Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9299283rdf:typepubmed:Citationlld:pubmed
pubmed-article:9299283lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:9299283lifeskim:mentionsumls-concept:C2709248lld:lifeskim
pubmed-article:9299283lifeskim:mentionsumls-concept:C0030899lld:lifeskim
pubmed-article:9299283lifeskim:mentionsumls-concept:C0242488lld:lifeskim
pubmed-article:9299283lifeskim:mentionsumls-concept:C0277785lld:lifeskim
pubmed-article:9299283lifeskim:mentionsumls-concept:C0599946lld:lifeskim
pubmed-article:9299283lifeskim:mentionsumls-concept:C1519957lld:lifeskim
pubmed-article:9299283pubmed:issue2lld:pubmed
pubmed-article:9299283pubmed:dateCreated1997-10-9lld:pubmed
pubmed-article:9299283pubmed:abstractTextAcute lung injury (ALI) is characterized by pulmonary hypertension. Although the pathophysiology of ALI is complex, cytokine production, especially tumor necrosis factor-alpha (TNF-alpha), is known to mediate histologic lung injury. Pentoxifylline (PTX) is known to inhibit the expression of many cytokines, including TNF-alpha. The purpose of this study was to determine the effect of PTX treatment on endotoxin-induced impairment of endothelium-dependent mechanisms of pulmonary vasorelaxation. Mechanisms of endothelium-dependent relaxation were studied with the muscarinic receptor agonist, acetylcholine (ACh), and the receptor-independent calcium ionophore, A23187. Endothelium-independent pulmonary vasorelaxation was examined by direct stimulation of smooth muscle guanylate cyclase with the nitric oxide donor, sodium nitroprusside (SNP). Five rats received PTX (50 mg/kg) and endotoxin (20 mg/kg), endotoxin alone, or saline ip. After 6 hr, dose-response curves to ACh, A23187, and SNP were determined in isolated pulmonary artery rings preconstricted with phenylephrine (PE). PTX attenuated but did not eliminate endotoxin-induced impairment of endothelium-dependent and -independent pulmonary vasorelaxation. These data suggest that PTX may offer a therapeutic modality for the treatment of pulmonary hypertension in ALI.lld:pubmed
pubmed-article:9299283pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9299283pubmed:languageenglld:pubmed
pubmed-article:9299283pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9299283pubmed:citationSubsetIMlld:pubmed
pubmed-article:9299283pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9299283pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9299283pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9299283pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9299283pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9299283pubmed:statusMEDLINElld:pubmed
pubmed-article:9299283pubmed:monthAuglld:pubmed
pubmed-article:9299283pubmed:issn0022-4804lld:pubmed
pubmed-article:9299283pubmed:authorpubmed-author:McIntyreR CRClld:pubmed
pubmed-article:9299283pubmed:authorpubmed-author:MeldrumD RDRlld:pubmed
pubmed-article:9299283pubmed:authorpubmed-author:FullertonD...lld:pubmed
pubmed-article:9299283pubmed:authorpubmed-author:SheridanB CBClld:pubmed
pubmed-article:9299283pubmed:copyrightInfoCopyright 1997 Academic Press.lld:pubmed
pubmed-article:9299283pubmed:issnTypePrintlld:pubmed
pubmed-article:9299283pubmed:volume71lld:pubmed
pubmed-article:9299283pubmed:ownerNLMlld:pubmed
pubmed-article:9299283pubmed:authorsCompleteYlld:pubmed
pubmed-article:9299283pubmed:pagination150-4lld:pubmed
pubmed-article:9299283pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:meshHeadingpubmed-meshheading:9299283-...lld:pubmed
pubmed-article:9299283pubmed:year1997lld:pubmed
pubmed-article:9299283pubmed:articleTitlePentoxifylline treatment attenuates pulmonary vasomotor dysfunction in acute lung injury.lld:pubmed
pubmed-article:9299283pubmed:affiliationDepartment of Surgery, University of Colorado, Denver, Colorado, USA.lld:pubmed
pubmed-article:9299283pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9299283pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9299283pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9299283lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9299283lld:pubmed